{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:20:28Z","timestamp":1768479628990,"version":"3.49.0"},"reference-count":25,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,1,24]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>European Association of Urology and UK National Institute for Health and Care Excellence guidelines recommend that all men with suspicions of prostate cancer should undergo prebiopsy contrast enhanced, that is, multiparametric prostate MRI. Subsequent prostate biopsies should also be performed if MRI is positive, that is, Prostate Imaging\u2013Reporting and Data System (PI-RADS) scores 3\u20135. However, several retrospective post hoc analyses have shown that this approach still leads to many unnecessary biopsy procedures. For example, 88%\u201396% of men with PI-RADS, three findings are still diagnosed with clinically non-significant prostate cancer or no cancer at all.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>This is a prospective, randomised, controlled, multicentre trial, being conducted in Finland, to demonstrate non-inferiority in clinically significant cancer detection rates among men undergoing prostate biopsies post-MRI and men undergoing prostate biopsies post-MRI only after a shared decision based on individualised risk estimation. Men without previous diagnosis of prostate cancer and with abnormal digital rectal examination findings and\/or prostate-specific antigen between 2.5 ug\/L and 20.0\u2009ug\/L are included. We aim to recruit 830 men who are randomised at a 1:1 ratio into control (all undergo biopsies after MRI) and intervention arms (the decision to perform biopsies is based on risk estimation and shared decision-making). The primary outcome of the study is the proportion of men with clinically significant prostate cancer (Gleason 4+3 prostate cancer or higher). We will also compare the overall biopsy rate, benign biopsy rate and the detection of non-significant prostate cancer between the two study groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>The study (protocol V.2.0, 4 January 2021) was approved by the Ethics Committee of the Hospital District of Southwest Finland (IORG number: 0001744, IBR number: 00002216; trial number: 99\/1801\/2019). Participants are required to provide written informed consent. Full reports of this study will be submitted to peer-reviewed journals, mainly urology and radiology.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"NCT04287088\">NCT04287088<\/jats:ext-link>; the study is registered at ClinicalTrials.gov.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-053118","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T11:31:35Z","timestamp":1650022295000},"page":"e053118","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0)"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct01864135","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02241122","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01864135","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02241122","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-4602","authenticated-orcid":false,"given":"Otto","family":"Ettala","sequence":"first","affiliation":[{"name":"Department of Urology, TYKS Turku University Hospital and University of Turku, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Jambor","sequence":"additional","affiliation":[{"name":"Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Medical Imaging Centre of Southwest Finland, TYKS Turku University Hospital, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Montoya Perez","sequence":"additional","affiliation":[{"name":"Medical Imaging Centre of Southwest Finland, TYKS Turku University Hospital, Turku, Varsinais-Suomi, Finland"},{"name":"Department of Computing, University of Turku, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjo","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[{"name":"Department of Urology, Satakunta Hospital District, Pori, Satakunta, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Kaipia","sequence":"additional","affiliation":[{"name":"Department of Urology, Tampere University, Tampere, Pirkanmaa, Finland"},{"name":"Department of Urology, Tampere University Hospital, Tampere, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heikki","family":"Seikkula","sequence":"additional","affiliation":[{"name":"Department of Urology, Central Finland Central Hospital, Jyvaskyla, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari T","family":"Syv\u00e4nen","sequence":"additional","affiliation":[{"name":"Department of Urology, TYKS Turku University Hospital and University of Turku, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Taimen","sequence":"additional","affiliation":[{"name":"Department of Pathology, TYKS Turku University Hospital, Turku, Varsinais-Suomi, Finland"},{"name":"Institute of Biomedicine, University of Turku, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Verho","sequence":"additional","affiliation":[{"name":"Medical Imaging Centre of Southwest Finland, TYKS Turku University Hospital, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Steiner","sequence":"additional","affiliation":[{"name":"Medical Imaging Centre of Southwest Finland, TYKS Turku University Hospital, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jani","family":"Saunavaara","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, TYKS Turku University Hospital, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Saukko","sequence":"additional","affiliation":[{"name":"Medical Imaging Centre of Southwest Finland, TYKS Turku University Hospital, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliisa","family":"L\u00f6yttyniemi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Turku, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D","family":"Sjoberg","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Vickers","sequence":"additional","affiliation":[{"name":"Integrative Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannu","family":"Aronen","sequence":"additional","affiliation":[{"name":"Medical Imaging Centre of Southwest Finland, TYKS Turku University Hospital, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bostr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Urology, TYKS Turku University Hospital and University of Turku, Turku, Varsinais-Suomi, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2025101813050884000_12.4.e053118.1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/0284186X.2017.1288298","article-title":"Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA","volume":"56","author":"Seikkula","year":"2017","journal-title":"Acta Oncol"},{"key":"2025101813050884000_12.4.e053118.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.043"},{"key":"2025101813050884000_12.4.e053118.3","unstructured":"Mottet N , Bellmunt J , Briers E . EAU \u2013 ESTRO \u2013 ESUR \u2013 SIOG guidelines on prostate cancer. EDN. presented at the EAU annual Congress Copenhagen 2018. 978-94-92671-02-8. Arnhem, The Netherlands: EAU Guidelines Office, 2018."},{"key":"2025101813050884000_12.4.e053118.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"2025101813050884000_12.4.e053118.5","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"2025101813050884000_12.4.e053118.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30569-2"},{"key":"2025101813050884000_12.4.e053118.7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/jmri.25641","article-title":"Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD trial)","volume":"46","author":"Jambor","year":"2017","journal-title":"J Magn Reson Imaging"},{"key":"2025101813050884000_12.4.e053118.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002813","article-title":"Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: a prospective multi-institutional trial","volume":"16","author":"Jambor","year":"2019","journal-title":"PLoS Med"},{"key":"2025101813050884000_12.4.e053118.9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2018.06.022","article-title":"Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging","volume":"74","author":"Gr\u00f6nberg","year":"2018","journal-title":"Eur Urol"},{"key":"2025101813050884000_12.4.e053118.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0219","article-title":"Assessment of the diagnostic accuracy of Biparametric magnetic resonance imaging for prostate cancer in Biopsy-Naive men: the Biparametric MRI for detection of prostate cancer (BIDOC) study","volume":"1","author":"Boesen","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2025101813050884000_12.4.e053118.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.023"},{"key":"2025101813050884000_12.4.e053118.12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eururo.2020.04.016","article-title":"Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence","volume":"78","author":"Vickers","year":"2020","journal-title":"Eur Urol"},{"key":"2025101813050884000_12.4.e053118.13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.euo.2019.08.008","article-title":"Prebiopsy IMPROD Biparametric magnetic resonance imaging combined with prostate-specific antigen density in the diagnosis of prostate cancer: an external validation study","volume":"3","author":"Knaapila","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"2025101813050884000_12.4.e053118.14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euo.2020.08.014","article-title":"Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the prostate magnetic resonance imaging outcome database (PROMOD)","volume":"4","author":"Falagario","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2025101813050884000_12.4.e053118.15","doi-asserted-by":"crossref","unstructured":"NICE . NICE Guidance - Prostate Cancer: Diagnosis and Management: \u00a9 NICE (2019) Prostate Cancer: Diagnosis and Management. 124. BJU international, 2019.","DOI":"10.1111\/bju.14809"},{"key":"2025101813050884000_12.4.e053118.16","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20840"},{"key":"2025101813050884000_12.4.e053118.17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj131"},{"key":"2025101813050884000_12.4.e053118.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"2025101813050884000_12.4.e053118.19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000530"},{"key":"2025101813050884000_12.4.e053118.20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11386"},{"key":"2025101813050884000_12.4.e053118.21","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"2025101813050884000_12.4.e053118.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025101813050884000_12.4.e053118.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025101813050884000_12.4.e053118.24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-Targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025101813050884000_12.4.e053118.25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamaoncol.2020.7589","article-title":"Comparison of multiparametric magnetic resonance Imaging-Targeted biopsy with systematic transrectal ultrasonography biopsy for Biopsy-Naive men at risk for prostate cancer: a phase 3 randomized clinical trial","volume":"7","author":"Klotz","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-053118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:05:19Z","timestamp":1760817919000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-053118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,15]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/bmjopen-2021-053118"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-053118","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}